Disclosed is a sustained-release pharmaceutical dosage form adapted for oral administration to a subject in need thereof, comprising a therapeutically effective amount of at least one bile acid sequestrant selected from colesevelam and colesevelam hydrochloride and a gastric-retention vehicle composition comprising one or more hydrogels, wherein said dosage form is adapted for use in preventing or treating an esophageal disorder selected from heartburn, erosive esophagitis, GERD, esophagitis, Barrett's esophagus, esophageal adenocarcinona and non-responsive GERD. Also disclosed is the use of the dosage form in the manufacture of a medicament for preventing or treating an esophageal disorder selected from heartburn, erosive esophagitis, GERD, esophagitis, Barrett's esophagus, esophageal adenocarcinona and non-responsive GERD.
